Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 222 clinical trials
featured
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Oral Ozanimod As Induction Therapy For Moderately To Severely Active Crohn’s Disease

This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease. Other studies available to continue treatment later after the initial 12 weeks period.  

  • 32 views
  • 23 Nov, 2020
  • 1 location
featured
A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

  • 82 views
  • 25 Mar, 2021
  • 1 location
Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

dividing. Giving bevacizumab together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase III trial is studying how well giving induction therapy with bevacizumab

combination chemotherapy
adjuvant therapy
tumor growth
capecitabine
irinotecan
  • 7 views
  • 07 Nov, 2020
  • 1 location
Observation Combination Chemotherapy Radiation Therapy and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. An autologous stem cell transplant may …

combination chemotherapy
filgrastim
tumor cells
cyclophosphamide
etoposide
  • 30 views
  • 07 Nov, 2020
  • 28 locations
A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).

  • 0 views
  • 16 May, 2021
  • 77 locations
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

All patients with multiple myeloma (MM) are destined to relapse even with the best available approved agents. Median OS from diagnosis in the current era is reported at 5.4 years. Given that myeloma remains an incurable disease, future improved OS is therefore reliant on the expansion of salvage options for …

  • 22 views
  • 21 Jan, 2021
  • 1 location
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. A donor stem cell transplant may replace the patient's immune cells …

combination chemotherapy
graft-versus-tumor
mercaptopurine
cytarabine
cyclophosphamide
  • 0 views
  • 07 Nov, 2020
  • 1 location
Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

burden and normalization of LDH. The investigators postulate that induction therapy with combined BRAF+MEK inhibition, and subsequent LDH normalization, can improve response rates to the rates

  • 5 views
  • 24 Jan, 2021
  • 13 locations
Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.

This study aimed to investigate the efficacy and safety of pegylated liposomal doxorubicin together with etoposide and methylprednisolone as a induction therapy for lymphoma induced

  • 0 views
  • 23 Jan, 2021
  • 1 location
XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

The purpose of this study is to determine the pathological complete response rate of addition of bevacizumab to induction therapy (xelox) and concomitant treatment (capecitabine

xelox
capecitabine
adenocarcinoma of rectum
liver metastases
metastasis
  • 7 views
  • 07 Nov, 2020
  • 1 location